Claudia Avitia-Domínguez, Erick Sierra-Campos, Irene Betancourt-Conde, Miriam Aguirre-Raudry, Alejandra Vázquez-Raygoza, Artemisa Luevano-De la Cruz, Alejandro Favela-Candia, Marie Sarabia-Sanchez, Lluvia Ríos-Soto, Edna Méndez-Hernández, Jorge Cisneros-Martínez, Marcelo Gómez Palacio-Gastélum, Mónica Valdez-Solana, Jessica Hernández-Rivera, Jaime De Lira-Sánchez, Mara Campos-Almazán and Alfredo Téllez-Valencia Pages 260 - 274 ( 15 )
Malaria is one of the main infectious diseases in tropical developing countries and represents high morbidity and mortality rates nowadays. The principal etiological agent P. falciparum is transmitted through the bite of the female Anopheles mosquito. The issue has escalated due to the emergence of resistant strains to most of the antimalarials used for the treatment including Chloroquine, Sulfadoxine-Pyrimethamine, and recently Artemisinin derivatives, which has led to diminished effectiveness and by consequence increased the severity of epidemic outbreaks. Due to the lack of effective compounds to treat these drug-resistant strains, the discovery or development of novel anti-malaria drugs is important. In this context, one strategy has been to find inhibitors of enzymes, which play an important role for parasite survival. Today, promising results have been obtained in this regard, involving the entire P. falciparum metabolism. These inhibitors could serve as leads in the search of a new chemotherapy against malaria. This review focuses on the achievements in recent years with regard to inhibition of enzymes used as targets for drug design against malaria.
Malaria, Plasmodium falciparum, enzyme inhibition, drug design.
Facultad de Medicina y Nutrición, Universidad Juárez del Estado de Durango, Av. Universidad y Fanny Anitua S/N, Durango. Dgo. México, C.P. 34000.